Elevated Levels of Prostate-Specific Antigen (PSA) in Prostate Cancer Cells Expressing Mutant p53 is Associated with Tumor Metastasis

Molecular Carcinogenesis

Volumn 38, Issue 3, 2003, Pages 130-140

  Downing, Sean ^b   Bumak, Clare ^b   Nixdorf, Sheri ^b   Ow, Kim ^b   Russell, Pamela ^b   Jackson, Paul ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b NONE

Author keywords

Prostate cancer progression and diagnosis; PSA; Tumor markers; Tumor suppressor genes

Indexed keywords

CISPLATIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; TUMOR MARKER;

ARTICLE; CANCER CELL; DNA DAMAGE; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; METASTASIS; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN SECRETION; ULTRAVIOLET RADIATION; VASCULARIZATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; HUMANS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 1; MICE; MICE, NUDE; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TRANSFECTION; TUMOR CELLS, CULTURED; ULTRAVIOLET RAYS; UP-REGULATION;

MUS MUSCULUS;

EID: 0242490099     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10154     Document Type: Article

References (44)

1. Candas B, Cusan L, Gomez JL, et al. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate 2000;45:19-35.
2. Montironi R, Mazzucchelli R, Algaba F, Bostwick DG, Krongrad A. Prostate-specific antigen as a marker of prostate disease. Virchows Arch 2000;436:297-304.
3. Riegman PHJ, Vlietstra RJ, van der Korput JAGM, Brinkmann AO, Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 1991;5:1921-1930.
4. Wirth MP, Froschermaier SE. The anti-androgen withdrawal syndrome. Urol Res 1997;25(Suppl 2):S67-S71.
5. Sadar MD. Androgen-independent induction of prostate specific antigen gene expression via cross-talk between androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 1999;274:7777-7783.
6. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: Molecular biology of early progression to androgen independence. Endocr Relat Cancer 1999;6:487-502.
7. Yeung F, Li X, Ellett J, Trapman J, Kao C, Chung LW. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem 2000;275:40846-40855.
8. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. The role of the p53 tumor suppressor gene in prostate cancer: A possible biomarker? Urology 1996;48:971-979.
9. Downing SR, Jackson P, Russell PJ. Mutations within the tumor suppressor gene p53 are not confined to a late event in prostate cancer progression - a review of the evidence. Urol Oncol 2001;6:103-110.
10. Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S, Moul JW. p53 nuclear protein expression is an independent prognostic marker in clinically localised prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1995;1:1295-1300.
11. Ko S, Gotoh A, Thalmann GN, et al. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum Gene Ther 1996;7:1683-1691.
12. Gurova KV, Roklin OW, Krivokrysenko VI, et al. Expression of prostate specific antigen is negatively regulated by p53. Oncogene 2002;21:153-157.
13. Shenk JL, Fisher CJ, Chen S, Zhou X, Tillman K, Shemshedini L. p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem 2001;276:38472-38479.
14. Hemsley AA. A simple method for the site-directed mutagenesis using the polymerase chain reaction. Nucl Acids Res 1989;17:6545-6551.
15. Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LWK. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 1996;88:794-801.
16. Yardley G, Zauberman A, Oren M, Jackson P. Individual promoter and intron p53-binding motifs from the rat Cyclin G1 promoter region support transcriptional activation by p53, but do not show co-operative activation. FEBS Lett 1998;430:171-175.
17. Jackson P, Millar D, Kingsley E, et al. Methylation of a CpG island within the promoter region of the KAI1 metastasis suppressor gene is not responsible for down-regulation of KAI1 expression in invasive cancers or cancer cell lines. Cancer Lett 1998;157:169-176.
18. Whittaker RG, Manthey MK, Le Broque DD, Hayes PJ. A microtiter plate assay for the characterisation of serine proteases by their esterase activity. Anal Biochem 1994;220:238-243.
19. Voeks D, Martiniello-Wilks R, Madden V, et al. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther 2002;9:759-768.
20. Russell PJ, Raghavan D, Gregory P, et al. Bladder cancer xenografts: A model of tumor cell heterogeneity. Cancer Res 1986;46:2035-2040.
21. Sun YB, Sun Y, Wenger L, Rutter JL, Brinckerhoff CE, Cheung HS. p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression. J Biol Chem 1999;274:11535-11540.
22. Mashimo T, Watabe M, Hirota S, et al. The expression of the KAI1 gene, a metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci USA 1998;95:11307-11311.
23. Lim DJ, Liu X, Sutkowski DM, Braun EJ, Lee C, Kozlowski JM. Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice. Prostate 1993;22:109-118.
24. Johnson RA, Ince TA, Scotto KW. Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 2001;276:27716-27720.
25. Roemer K. Mutant p53: Gain-of-function oncoproteins and wild-type p53 inactivators. Biol Che Hoppe-Seyler 1999;380:879-887.
26. Ludes-Meyers JH, Subler MA, Shivakumar CV, et al. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 1996;16:6009-6019.
27. Pugacheva EN, Ivanov AV, Kravchenko JE, Kopnin BP, Levine AJ, Chumakov PM. Novel gain of function activity of p53 mutants: Activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 2002;21:4595-4600.
28. Iwanaga Y, Jiang KT. Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by gain-of-function p53 mutant. Cancer Res 2002;62:2618-2624.
29. Lanyi A, Deb D, Seymour RC, Ludes-Meyers JH, Subler MA, Deb S. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/non-sequence-specific nucleic acid-binding domain. Oncogene 1998;16:3169-3176.
30. Ginsberg D, Mechta F, Yaniv M, Oren M. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 1991;88:9979-9983.
31. Sun Z, Pan J, Balk SP. Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes. Nucl Acids Res 1997;25:3318-3325.
32. Kley N, Chung RY, Fay S, Loeffler JP, Seizinger BR. Repression of the basal c-fos promoter by wild-type p53. Nucl Acids Res 1992;20:4083-4087.
33. Koivisto PA, Rantala I. Amplification of the androgen receptor gene is associated with p53 mutation in hormone-refractory recurrent prostate cancer. J Pathol 1999;187:237-241.
34. Yang G, Stapleton AMF, Wheeler TM, et al. Clustered p53 immunostaining-a novel pattern associated with prostate cancer progression. Clin Cancer Res 1996;2:399-401.
35. Quinn DI, Henshall SM, Head DR, et al. Prognostic significance of p53 nuclear accumulation in localised prostate cancer treated with radical prostatectomy. Cancer Res 2000;60:1585-1594.
36. Stapleton AMF, Timme TL, Gousse AE, et al. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 1997;3:1389-1397.
37. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, deVere White RW. Very frequent p53 mutations in metastatic prostate carcinoma and its matched primary tumors. Cancer 1998;83:2534-2539.
38. Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-1669.
39. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-1584.
40. Grossveld GD, Ginsberg DA, Stein JP, et al. Thrombospondin-1 expression in bladder cancer-association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997;89:219-227.
41. Bouvet M, Ellis LM, Nishizaki M, et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1996;58:2288-2292.
42. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;9:963-969.
43. Zou Z, Gao C, Nagaich AK, et al. p53 regulates expression of the tumor suppressor gene maspin. J Biol Chem 2000;275:6051-6054.
44. Sun Y, Cheung JM, Martel-Pelletier J, et al. Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem 2000;275:11327-11332.